Mouse anti-Human DAF Monoclonal Antibody | anti-DAF antibody
DAF, Human, mAb 1C6
Reactivity
Human
Applications
Flow Cytometry, Functional Assay, Western Blot
Synonyms
DAF; Monoclonal Antibody; Human; mAb 1C6; CD55; anti-DAF antibody
Host
Mouse
Reactivity
Human
Clonality
Monoclonal
Isotype
Mouse IgG1
Clone Number
1C6
Form/Format
1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin.
For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
Applicable Applications for anti-DAF antibody
Flow Ctometry (FC/FACS), Functional Studies (FS), Immuno Assay (IA), Western Blot (WB)
Application Notes
For flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting..
Immunogen
Purified DAF from pooled human erythrocyte stroma
Preparation and Storage
Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.-
Related Product Information for anti-DAF antibody
The monoclonal antibody 1C6 recognizes human complement decay-accelerating factor (DAF), also designated as CD55. Cells express on their surface several proteins which protect against complement attack, namely complement receptor I (CR1), decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP).
Human DAF (CD55) is a protein of 381 amino acids resulting in a ~ 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. It belongs to the receptors of complement activation (RCA) family. DAF is broadly distributed among cells in contact with plasma complment proteins, including both haematopoietic and non-haematopoietic cells. Although DAF does not have an essential role in controling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells.
Together with other complement regulators DAF protects self cells from autologous complement-mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. DAF is overexpressed in certain tumors thereby limiting the complement-dependent cytotoxiticy of therapeutic anticancer antibodies. Using DAF blocking antibodies targeted specifically at cancer cells in combination with immunotherapeutic monoclonal antibodies of cancer may improve the therapeutic effect in cancer patients.
Human DAF (CD55) is a protein of 381 amino acids resulting in a ~ 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. It belongs to the receptors of complement activation (RCA) family. DAF is broadly distributed among cells in contact with plasma complment proteins, including both haematopoietic and non-haematopoietic cells. Although DAF does not have an essential role in controling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells.
Together with other complement regulators DAF protects self cells from autologous complement-mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. DAF is overexpressed in certain tumors thereby limiting the complement-dependent cytotoxiticy of therapeutic anticancer antibodies. Using DAF blocking antibodies targeted specifically at cancer cells in combination with immunotherapeutic monoclonal antibodies of cancer may improve the therapeutic effect in cancer patients.
References
1. Fujita, T et al; The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987, 166: 1221. 2. Higuchi, M et al; Identification of the decay-accelerating factor CD55 as a peanut agglutinin-binding protein and its alteration in non-small cell lung cancers. Clin Cancer Res 2006, 12: 6367
3. Xu, H et al; Investigation of cynomolgus monkey complement. Transplantation Proceedings 2008, 40: 607
4. Okura, E et al; Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF. Xenoptransplantation 2008, 15: 365
3. Xu, H et al; Investigation of cynomolgus monkey complement. Transplantation Proceedings 2008, 40: 607
4. Okura, E et al; Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF. Xenoptransplantation 2008, 15: 365
Similar Products
Product Notes
The DAF (Catalog #AAA584669) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The DAF, Human, mAb 1C6 reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's DAF can be used in a range of immunoassay formats including, but not limited to, Flow Ctometry (FC/FACS), Functional Studies (FS), Immuno Assay (IA), Western Blot (WB). For flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.. Researchers should empirically determine the suitability of the DAF for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "DAF, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
